Loading...
•
Dec 31, 2019
SpringWorks Therapeutics Q4 2019 Earnings Report
SpringWorks Therapeutics reported financial results for the fourth quarter of 2019 and provided an update on recent company developments.
Key Takeaways
SpringWorks Therapeutics reported a net loss of $16.2 million for the fourth quarter of 2019. The company's cash and cash equivalents totaled $327.7 million as of December 31, 2019. They initiated a Phase 1 clinical trial of BGB-3245 and entered into a clinical collaboration agreement with Allogene Therapeutics.
Initiated a Phase 1 clinical trial of BGB-3245, a selective next-generation B-RAF inhibitor.
Entered into a clinical collaboration agreement with Allogene Therapeutics to evaluate nirogacestat in combination with ALLO-715.
Presented data at the American Society of Hematology meeting showing activity of nirogacestat alone and in combination with GlaxoSmithKline’s belantamab mafodotin.
Dosed the first patients in the Phase 2b ReNeu clinical trial evaluating mirdametinib in children and adults with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...